spacer
home > ebr > winter 2003 > contract manufacturing for small biotechs
PUBLICATIONS
European Biopharmaceutical Review

Contract Manufacturing for Small Biotechs

Much has been written recently about the burgeoning growth of biopharmaceutical business and the looming capacity crunch in biologics manufacture. Numerous enterprises are investing heavily in the production of stainless steel so that they are positioned to churn out lucrative, premium-priced biopharmaceuticals that are already approved or forecast to be approved in the coming years. The emergence of biopharmaceuticals as effective therapeutics, coupled with a trend to outsource biologic manufacturing, has led to unprecedented growth in 'third party' contract manufacturing organisations (CMOs) and much of the additional capacity will come from that sector. Here in Canada for example, a €100 million expansion to provide 60,000L of animal cell culture capability has recently been announced by DSM Biologics.

Many of the CMOs are positioning themselves to capture the long-term, large-volume supply contracts offered by big pharma or big biotech that are more lucrative than the high-risk developmental projects typical of smaller, early-stage biotech companies trying to get their products into the clinic for the first-in-man trials. Due to the high risk of failure for early-stage biotech projects, the chances of them eventually leading to long-term supply agreements are relatively small.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr David Cox, PhD, CEO of KS Avicenna Inc

Dr David Cox is CEO of KS Avicenna Inc, a cGMP contract manufacturer of fermentation-derived biologies. He has more than 25 years of experience in the biotechnology and pharmaceutical industries in both the UK and Canada. Prior to his appointment with KS Avicenna, Dr Cox was CEO of Synsorb Biotech Inc, a publicly traded biotech company listed on the TSE and Nasdaq. Dr Cox's experience also includes CEO of Apotex Fermentation Inc and VP Advanced Technologies for the Alberta Research Council.

spacer
Dr David Cox
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical Trial Supply West Coast Conference 2019

Philadelphia, USA – April 24, 2019. This year’s Clinical Trial Supply West Coast Conference will see leading biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) showcasing its specialist clinical trials expertise in relation to scheduled drugs.
More info >>

White Papers

Key to Outsourcing Method Development and Validation A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation.
More info >>

 
Industry Events

CPhI & P-MEC China

18-20 June 2019, SNIEC, Shanghai, China

CPhI & P-MEC China 2019 is your gateway to successfully grow your business at the 2nd largest pharma market in the world. Whether you are looking for sourcing new business or getting the latest market insight, this is your one-stop shop pharmaceutical platform in Asia.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement